Product Description
Sanofi is developing an anti-TNFa/OX40L Nanobody VHH for the treatment of Inflammatory diseases. (Sourced from: https://www.sanofi.com/dam/jcr:7b69cea0-7ef9-420b-a9b5-cd43e204929a/2023_02_03_Sanofi_Q4FY_2022_Results_Presentation.pdf)
Mechanisms of Action: TNFa Inhibitor, OX40L Antagonist
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sanofi
Company Location: Europe
Company Founding Year: 1973
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Saudi Arabia, Slovakia, Spain, Sweden, Taiwan, United Arab Emirates, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 15
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Sanofi presented P2 Hidradenitis Suppurativa results on 2025-09-17 for Brivekimig
- Clinical Outcomes Reported - Sanofi presented P2 Hidradenitis Suppurativa results on 2025-09-19 for Brivekimig
Highest Development Phases
Phase 2: Colitis, Ulcerative|Crohn Disease|Glomerulonephritis|Glomerulosclerosis, Focal Segmental|Hidradenitis Suppurativa|Nephrosis, Lipoid|Proteinuria|Type 1 Diabetes
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06812988 |
T1D OBTAIN | P2 |
Active, not recruiting |
Type 1 Diabetes |
2027-04-29 |
12% |
2026-03-17 |
Primary Endpoints |
NCT06500702 |
RESULT | P2 |
Recruiting |
Glomerulosclerosis, Focal Segmental|Glomerulonephritis|Nephrosis, Lipoid |
2026-12-23 |
50% |
2025-10-23 |
Primary Endpoints|Start Date|Treatments |
NCT06975722 |
COLOR UC | P2 |
Recruiting |
Colitis, Ulcerative |
2026-12-17 |
12% |
2025-07-08 |
Primary Endpoints|Start Date |
NCT06958536 |
CHROMA CD | P2 |
Recruiting |
Crohn Disease |
2026-12-17 |
12% |
2025-07-08 |
|
2024-511775-15-00 |
ACT18064 | P2 |
Recruiting |
Proteinuria|Glomerulosclerosis, Focal Segmental |
2028-02-28 |
2025-05-02 |
Treatments |
|
NCT07170917 |
BRIGHTEN | P2 |
Recruiting |
Hidradenitis Suppurativa |
2027-08-01 |
12% |
2026-05-23 |
Primary Endpoints|Treatments |
jRCT2031250434 |
jRCT2031250434 | P2 |
Recruiting |
Hidradenitis Suppurativa |
2028-04-27 |
|||
2022-502370-17-00 |
ACT16852 | P2 |
Completed |
Hidradenitis Suppurativa |
2025-01-09 |
2025-05-02 |
Treatments |
|
jRCT2071230056 |
jRCT2071230056 | P1 |
Recruiting |
Healthy Volunteers |
2024-01-31 |
|||
NCT05849922 |
HS OBTAIN | P2 |
Completed |
Hidradenitis Suppurativa |
2024-08-22 |
12% |
2025-01-24 |
Primary Endpoints|Study Completion Date |
jRCT2021250015 |
jRCT2021250015 | P2 |
Recruiting |
Colitis, Ulcerative |
2030-02-17 |
|||
2024-515241-41-00 |
ACT18134 | P2 |
Not yet recruiting |
Colitis, Ulcerative |
2029-11-29 |
12% |
||
2024-517016-30-00 |
DRI18450 | P2 |
Not yet recruiting |
Crohn Disease |
2029-11-01 |
12% |
||
jRCT2021250009 |
jRCT2021250009 | P2 |
Recruiting |
Crohn Disease |
2029-04-30 |
|||
2025-522333-61-00 |
DRI19220 | P2 |
Not yet recruiting |
Hidradenitis Suppurativa |
2028-05-25 |
12% |
Recent News Events
Date |
Type |
Title |
|---|